Based on available information, yes, Deloitte practices elements of agentic science, particularly through its extensive work in agentic AI applied to life sciences research and development (R&D). This includes using autonomous AI agents to synthesize clinical study data, author complex R&D documents, accelerate time-to-market for therapies, and orchestrate personalized multi-device treatment pathways (e.g., coordinating tools like electrocardiograms, ablation solutions, heart pumps, and atrial shunts for cardiovascular conditions).
Deloitte also offers broader agentic AI solutions tailored for the life sciences value chain, such as the Agentic Patient Services suite built on Salesforce's Agentforce platform. This deploys multi-agent systems to automate patient onboarding (reducing manual processes by 50-70%), monitor adherence, and create personalized engagement plans based on risk assessments and historical data—enhancing operational efficiency in clinical and care management contexts.
These applications align with the core concept of agentic science, where AI agents semi-autonomously reason, plan, and execute tasks to advance scientific discovery and processes in fields like health care and biotechnology. Deloitte's research further indicates strong investment in agentic AI for health care, with over 80% of executives expecting significant value in clinical functions by 2026.